On September 14, the Food and Drug Administration held a public hearing in collaboration with federal partners to obtain feedback and perspectives on issues associated with the potential future therapeutic use of drug products containing a psychedelic drug substance in supervised and supportive settings. The event was entitled Considerations for Potential Future Therapeutic Use of Psychedelic Drugs. We’ll hear opening remarks from Marta Sokolowska, Ph.D., Senior Policy Advisor in FDA’s Office of Policy, Legislation, and International Affairs, and Deputy Center Director for Substance Use and Behavioral Health at FDA’s Center for Drug Evaluation and Research. We’ll also hear testimony from some of the witnesses including Columbia University Professor Heidi Allen, PhD; Dr. Lynn Marie Morski, Executive Director of the Psychedelic Medicine Association; Lakisha Jenkins-Samuels, PhD, founder and president of the Kiona Foundation; Dr. Heather Kuiper, President of the Center for Psychedelic Public Health; Dr. Corey Whetzel, Senior Manager of Regulatory Affairs at the American Pharmacists Association; Edward Jacobs, PhD, a Postdoctoral Research Fellow at the Center for Psychedelic and Consciousness Research at the Johns Hopkins School of Medicine; Eric Jansen, Government Affairs Coordinator at the Balanced Veterans Network; Melissa Lavasani, founder and CEO of the Psychedelic Medicine Coalition; Alia Lilienstein, MD, a Research Physician at the University of California Berkeley Center for the Science of Psychedelics; and Jorge Valderrabano, CEO and Board Member of Agora.